首页 › 基金 › Frazier Life Sciences Management, L.P. › LXEO
Frazier Life Sciences Management, L.P. 对 LXEO 的持仓历史
LEXEO THERAPEUTICS INC COM · 医疗保健
Frazier Life Sciences Management, L.P. 在 Q2 2026 的 13F 申报中披露持有 LXEO(LEXEO THERAPEUTICS INC COM)4,824,725 股,市值约 US$22.5M,约占其申报组合的 0.49%,在其申报持仓中市值排名第 33 位。 Frazier Life Sciences Management, L.P. 最近 8 个申报季度中有 8 个季度披露了 LXEO 持仓,最早可追溯至 Q3 2024。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Frazier Life Sciences Management, L.P. 对 LXEO 的持仓演变
Frazier Life Sciences Management, L.P. 于 Q3 2024 首次披露 LXEO 持仓:1,250,786 股(约 US$11.3M)。 该持仓在 Q4 2025 达到峰值 4,424,725 股,市值约 US$43.9M。 在 8 次申报中,Frazier Life Sciences Management, L.P. 2 次增持、1 次减持、4 次保持不变。 最近一期申报(Q2 2026)显示持股 4,824,725 股、市值约 US$22.5M,环比增持 400,000 股。。 持仓曾出现大幅变动:Q2 2025 增持约 363% (随后一个季度股价上涨 65%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2024 | 1.25M | $11.31M | 新进 |
| Q4 2024 | 955.51K | $6.29M | 减持 |
| Q1 2025 | 955.51K | $3.32M | 持有 |
| Q2 2025 | 4.42M | $17.79M | 增持 |
| Q3 2025 | 4.42M | $29.38M | 持有 |
| Q4 2025 | 4.42M | $43.94M | 持有 |
| Q1 2026 | 4.42M | $25.40M | 持有 |
| Q2 2026 | 4.82M | $22.46M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 LXEO 与 13F 数据
LXEO(LEXEO THERAPEUTICS INC COM)属于医疗保健行业。我们追踪的基金中还有 40 只申报持有 LXEO,申报仓位最大的包括:MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Vestal Point Capital, LP (US$20.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 LXEO 的基金
- MONTANOVA CAPITAL, LLC 6.38M 股 · $29.72M · Q2 2026
- Affinity Asset Advisors, LLC 5.81M 股 · $27.03M · Q2 2026
- Vestal Point Capital, LP 4.32M 股 · $20.11M · Q2 2026
- Paradigm Biocapital Advisors LP 4.18M 股 · $19.44M · Q2 2026
- 683 Capital Management, LLC 1.88M 股 · $8.73M · Q2 2026
- Avoro Capital Advisors LLC 1.49M 股 · $6.93M · Q2 2026
- Spruce Street Capital LP 928.59K 股 · $4.32M · Q2 2026
- DAFNA Capital Management LLC 377.06K 股 · $1.76M · Q2 2026
更多关于 Frazier Life Sciences Management, L.P.
常见问题
How long has Frazier Life Sciences Management, L.P. held LXEO?
Frazier Life Sciences Management, L.P. has disclosed LXEO holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is Frazier Life Sciences Management, L.P.'s current position in LXEO?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 4.82M shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $22.46M, representing 0.49% of its reported portfolio and ranking #33.
Has Frazier Life Sciences Management, L.P. been buying or selling LXEO?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. increased its position in LXEO. The position peaked in Q4 2025 at 4.42M shares.
Which other funds hold LXEO?
Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Vestal Point Capital, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.